1012 related articles for article (PubMed ID: 22077144)
21. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
Kakkar AK; Brenner B; Dahl OE; Eriksson BI; Mouret P; Muntz J; Soglian AG; Pap AF; Misselwitz F; Haas S;
Lancet; 2008 Jul; 372(9632):31-9. PubMed ID: 18582928
[TBL] [Abstract][Full Text] [Related]
22. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
[TBL] [Abstract][Full Text] [Related]
23. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
[TBL] [Abstract][Full Text] [Related]
24. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
25. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
; Büller HR; Décousus H; Grosso MA; Mercuri M; Middeldorp S; Prins MH; Raskob GE; Schellong SM; Schwocho L; Segers A; Shi M; Verhamme P; Wells P
N Engl J Med; 2013 Oct; 369(15):1406-15. PubMed ID: 23991658
[TBL] [Abstract][Full Text] [Related]
26. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
Bergmann JF; Neuhart E
Thromb Haemost; 1996 Oct; 76(4):529-34. PubMed ID: 8902991
[TBL] [Abstract][Full Text] [Related]
27. Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis.
King DA; Pow RE; Dickison DM; Vale PR
Intern Med J; 2016 Sep; 46(9):1030-7. PubMed ID: 27246450
[TBL] [Abstract][Full Text] [Related]
28. Extended-duration thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate ligament: a prospective, randomized, placebo-controlled study.
Marlovits S; Striessnig G; Schuster R; Stocker R; Luxl M; Trattnig S; Vécsei V
Arthroscopy; 2007 Jul; 23(7):696-702. PubMed ID: 17637403
[TBL] [Abstract][Full Text] [Related]
29. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
Weitz JI; Bauersachs R; Becker B; Berkowitz SD; Freitas MCS; Lassen MR; Metzig C; Raskob GE
JAMA; 2020 Jan; 323(2):130-139. PubMed ID: 31935028
[TBL] [Abstract][Full Text] [Related]
30. Apixaban: an oral direct factor-xa inhibitor.
Jiménez D; Yusen RD; Ramacciotti E
Adv Ther; 2012 Mar; 29(3):187-201. PubMed ID: 22354465
[TBL] [Abstract][Full Text] [Related]
31. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
Weitz JI; Cao C; Eriksson BI; Fisher W; Kupfer S; Raskob G; Spaeder J; Turpie AG
Thromb Haemost; 2010 Dec; 104(6):1150-7. PubMed ID: 20886185
[TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial.
Guntupalli SR; Brennecke A; Behbakht K; Tayebnejad A; Breed CA; Babayan LM; Cheng G; Ramzan AA; Wheeler LJ; Corr BR; Lefkowits C; Sheeder J; Matsuo K; Flink D
JAMA Netw Open; 2020 Jun; 3(6):e207410. PubMed ID: 32589230
[TBL] [Abstract][Full Text] [Related]
33. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Bergqvist D; Agnelli G; Cohen AT; Eldor A; Nilsson PE; Le Moigne-Amrani A; Dietrich-Neto F;
N Engl J Med; 2002 Mar; 346(13):975-80. PubMed ID: 11919306
[TBL] [Abstract][Full Text] [Related]
34. Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial.
Liu X; Johnson M; Mardekian J; Phatak H; Thompson J; Cohen AT
J Am Heart Assoc; 2015 Dec; 4(12):. PubMed ID: 26627879
[TBL] [Abstract][Full Text] [Related]
35. The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
Gibson CM; Halaby R; Korjian S; Daaboul Y; Arbetter DF; Yee MK; Goldhaber SZ; Hull R; Hernandez AF; Lu SP; Bandman O; Leeds JM; Gold A; Harrington RA; Cohen AT;
Am Heart J; 2017 Mar; 185():93-100. PubMed ID: 28267480
[TBL] [Abstract][Full Text] [Related]
36. Apixaban for extended treatment of venous thromboembolism.
Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Porcari A; Raskob GE; Weitz JI;
N Engl J Med; 2013 Feb; 368(8):699-708. PubMed ID: 23216615
[TBL] [Abstract][Full Text] [Related]
37. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Chi G; Goldhaber SZ; Kittelson JM; Turpie AGG; Hernandez AF; Hull RD; Gold A; Curnutte JT; Cohen AT; Harrington RA; Gibson CM
J Thromb Haemost; 2017 Oct; 15(10):1913-1922. PubMed ID: 28762617
[TBL] [Abstract][Full Text] [Related]
38. Dalteparin versus unfractionated heparin in critically ill patients.
; Cook D; Meade M; Guyatt G; Walter S; Heels-Ansdell D; Warkentin TE; Zytaruk N; Crowther M; Geerts W; Cooper DJ; Vallance S; Qushmaq I; Rocha M; Berwanger O; Vlahakis NE
N Engl J Med; 2011 Apr; 364(14):1305-14. PubMed ID: 21417952
[TBL] [Abstract][Full Text] [Related]
39. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Ma G; Zhang R; Wu X; Wang D; Ying K
Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
[TBL] [Abstract][Full Text] [Related]
40. Apixaban or enoxaparin for thromboprophylaxis.
Gómez-Outes A; Suárez-Gea ML; Pozo-Hernández C
N Engl J Med; 2009 Nov; 361(21):2100-1; author reply 2101. PubMed ID: 19923583
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
